Novavax, Inc. is a global biotechnology company committed to helping address serious infectious diseases globally through the discovery, development, and delivery of innovative vaccines to patients around the world.

Our mission

We never rest in our quest to protect the health of people everywhere.

Novavax is here to make a difference. We're a biotech company focused solely on developing life-saving vaccines to fight infectious diseases.

Our commitment is backed by solid science tested by decades of research, vaccines developed from trusted technology and a global network that will help to ensure our vaccines reach everyone who needs them.

Our ESG Approach

Novavax is on a mission to protect the health of people everywhere and follow the highest standards of corporate governance. Learn more about our Environmental, Social and Governance (ESG) initiatives.

Environmental, social, and governance image

Select local leaders

Jakub Kronovetr, PhD
Jakub Kronovetr, PhD
Site Director,
Novavax CZ
Eva Kuncová
Eva Kuncová
Finance and HR Director,
Novavax CZ
Alvar Paz
Alvar Paz
General Manager,
Commercial Strategy,
Dirk Poelaert
Dirk Poelaert
Senior Director,
Medical Affairs,
How to contact Novavax
General inquiries

+420 228 880 267
09:00 - 17:00
Monday - Friday

Our location: Líbalova 2348/1, Chodov, 149 00 Prague 4, Czech Republic  

Production site: Bohumil 138, 281 63 Jevany, Czech Republic

Media contact
Investor contact

To contact a member of the investor relations team, click on the "Contact us" button below.

Novavax CZ history

After World War I, the production section of the first State Health Institute of the Czechoslovak Republic was established in Bohumil on the territory of a former farmstead. Its task was to develop and produce sera and vaccines and to control the quality of food and medicines.

After World War II, the State Health Institute moved to Prague and only the part producing sera and vaccines remained in Bohumil. After the Velvet Revolution it was decided to build a plasma processing plant. However, it was never completed and in 2001 the production facility was purchased by the American company Baxter.

Until 2015, Baxter produced seasonal and pandemic influenza vaccines using advanced serum-free Vero cell technology. Subsequently, the company was owned by the Serum Institute of India, the largest vaccine manufacturer in the world. As the coronavirus pandemic emerged, the plant was acquired by the US company Novavax in 2020.